Cytokinetics, Inc.(NASDAQ : CYTK)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-0.46%||8.65||0.7%||$604.67m|
|GILD||Gilead Sciences, Inc.||-0.70%||71.19||1.0%||$455.28m|
|REGN||Regeneron Pharmaceuticals, Inc.||-1.18%||638.90||2.7%||$418.56m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.80%||183.61||1.9%||$245.25m|
|ISEE||IVERIC bio, Inc.||0.86%||16.37||0.0%||$193.25m|
|DVAX||Dynavax Technologies Corp.||1.17%||19.83||5.7%||$156.65m|
|LIFE||aTyr Pharma, Inc.||-17.87%||10.25||2.1%||$156.36m|
Cytokinetics, Inc. operates as a biopharmaceutical company. The firm focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.